# perpetuity. It is made available under a CC-BY 4.0 International license

# Investigating the effects of accelerated partner therapy (APT) on chlamydia transmission in Britain: a mathematical modelling study з

Christian L. Althaus<sup>\*1</sup>, Catherine H. Mercer<sup>2</sup>, Jackie A. Cassell<sup>3</sup>, Claudia

S. Estcourt<sup>4</sup>, and Nicola Low<sup>1</sup> 5

<sup>1</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland 6

<sup>2</sup>Institute for Global Health, University College London, London, UK 7

<sup>3</sup>Brighton and Sussex Medical School, East Sussex, UK 8

<sup>4</sup>School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK 9

### ABSTRACT 10

Understanding the effects of partner notification (PN) on the transmission of chlamydia, the 11 most prevalent bacterial sexual transmitted infection worldwide, is critical for implementing 12 optimal control strategies. Accelerated partner therapy (APT) aims to increase the numbers 13 of partners treated and reduce the time to partner treatment. Our objective was to study the 14 effects of APT interventions on partner treatment and chlamydia transmission in order to better 15 understand the results of LUSTRUM, an APT cross-over cluster randomised controlled trial in 16 the UK. We developed a novel deterministic, population-based chlamydia transmission model 17 including the process of PN. We considered a population aged 16-34 years and calibrated the 18 model to sexual behaviour data between people of the opposite-sex and chlamydia prevalence 19 data reported by 3,671 participants in Britain's third National Survey of Sexual Attitudes 20 and Lifestyles (Natsal-3, 2010–2012) using Approximate Bayesian Computation (ABC). We 21 investigated the potential effects of APT on chlamydia transmission by increasing the number 22 of treated partners and reducing the time to partner treatment compared to standard PN. 23 The median prevalence of chlamydia in the model was 1.84% (95% credible interval, Crl: 24 1.60%-2.62%) in women and 1.78% (95% Crl: 1.13%-2.14%) in men. Chlamydia positivity was 25 highest in partners of symptomatic index cases with low sexual activity. Infected partners were 26 typically asymptomatic and belonged to the high sexual activity group, i.e., are naturally those 27 infected individuals that will contribute most to onward transmission. Reducing the time to 28 partner treatment without achieving higher numbers of partners treated had only minor effects 29 on reducing chlamydia prevalence. In contrast, the model predicts that a potential increase 30 in the number of partners treated from current levels in Britain (0.51, 95% Crl: 0.21–0.80) by 31 25% would reduce chlamydia prevalence by 18% (95% Crl: 5%–44%) in both women in men 32 within 5 years. These results suggest that APT, through a potential increase in the proportion 33 of partners treated, would be an effective method to reduce ongoing chlamydia transmission in 34

Britain. 35

### INTRODUCTION 36

Partner notification (PN) is considered an important intervention contributing to the control of 37

- *Chlamydia trachomatis* (chlamydia) infection. Chlamydia is the most common bacterial sexually 38
- transmitted infection (STI) worldwide and primarily found among young sexually active adults 39
- (Rowley et al., 2019). Treatment and prevention of chlamydia are of particular importance to 40
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. \*Corresponding author: christian.althaus@alumni.ethz.ch

perpetuity. It is made available under a CC-BY 4.0 International license .

women since infection can lead to serious reproductive tract complications (Cates and Wasserheit, 41 1991). Most infections are asymptomatic and remain undiagnosed, however. PN involves the 42 identification and treatment of sexual partners exposed to infection to prevent re-infection of 43 the index case and prevent onward transmission (Organization and on HIV/AIDS, 1999). The 44 direct effects of PN on the identification of new cases and prevention of re-infection of index 45 cases are well-documented (Golden et al., 2005; Ferreira et al., 2013; Low et al., 2014). The 46 indirect population-level effects of PN on chlamydia transmission, incidence and prevalence are 47 less clear (Golden et al., 2015; Althaus et al., 2012a). 48 Accelerated partner therapy (APT) is a promising PN strategy, which aims to reduce the 49 time to partner treatment and increase the proportion of partners treated (Estcourt et al., 2012, 50 2015). APT is an adaption of expedited partner therapy (EPT) (Golden et al., 2015). The 51

difference between the strategies is that APT includes a clinical assessment of sex partners
 through telephone-led or face-to-face consultation with an appropriately qualified healthcare

<sup>54</sup> professional. APT could increase the uptake of PN towards, or even beyond, national targets.
 <sup>55</sup> Audits of data collected by the National Chlamydia Screening Programme (NCSP) showed that

<sup>55</sup> Audits of data collected by the National Chlamydia Screening Programme (NCSP) showed that <sup>56</sup> PN uptake (the number of contacts per index case who were reported as having attended a sexual

<sup>56</sup> FIN uptake (the humber of contacts per index case who were reported as having attended a sexual
 <sup>57</sup> health service within four working weeks of the date of the PN consultation) decreased from 0.53
 <sup>58</sup> in 2016 to 0.42 in 2017 and was below the standard of 0.6 (Public Health England, 2018). The

<sup>59</sup> national average for the time to attending a health service was 3.2 days (Public Health England,

<sup>60</sup> 2016). An exploratory trial of APT resulted in 59% (95% confidence interval, CI: 49%–69%)

and 66% (95% CI: 52%–78%) of contactable partners treated in two APT models (telephone

<sup>62</sup> hotline and pharmacy), compared to 36% (95% CI: 26%–47%) for standard PN (Estcourt et al.,

<sup>63</sup> 2012). This suggest that APT has the potential to increase the effective PN uptake. Furthermore,

the study found the median time (range) from diagnosis of the index case to partner treatment at

1 (0-14) day and 1 (0-6) day for the two APT models and 4 (0-17) days for standard PN.

Reliable estimates of the effects of APT are needed. The Limiting Undetected Sexually 66 Transmitted infections to RedUce Morbidity (LUSTRUM) programme is a cross-over cluster 67 randomised controlled trial (RCT) in the UK that aims to determine the effectiveness of APT 68 among opposite-sex partners with chlamydia (https://www.lustrum.org.uk). The 69 APT intervention is offered at the level of the sexual health clinic as an additional PN method 70 compared with standard PN (Estcourt et al., 2020). The trial is accompanied by mathematical 71 modelling of chlamydia transmission that we present here in order to better understand the 72 results from the trial and to quantify the effects of APT at the population level. The modelling 73 results will later feed into an economic evaluation for estimating the cost-effectiveness of APT 74 compared to standard PN (Roberts et al., 2012). 75

Mathematical modelling studies of chlamydia transmission have been widely used to explore 76 and understand the expected population-level effects of screening and PN interventions (Althaus 77 et al., 2012a, 2014; Rönn et al., 2017). Considerable progress in the understanding of chlamydia 78 transmission has been made, but substantial challenges remain. First, it proves difficult to 79 accurately describe the complex sexual contact structure among young adults which is necessary 80 to model PN interventions. Individual-based models offer great flexibility to trace an individual's 81 partnership history in detail but are difficult to parameterise (Althaus et al., 2012b). In contrast, 82 deterministic, population-based models are much more flexible to fit to epidemiological data, 83 but often restrict PN to ongoing (current) sexual partnerships only (Heijne et al., 2011; Rönn 84 et al., 2019). Second, the lack of data about chlamydia prevalence in the general population 85 before the introduction of screening for asymptomatic people and PN represents a major source 86 of uncertainty for the parameterisation of mathematical models. For example, a recent modelling 87 study estimated that chlamydia prevalence in the US population would have been almost twice 88

perpetuity. It is made available under a CC-BY 4.0 International license

the current levels in the absence of screening and PN (Rönn et al., 2019). Third, assumptions 89 about the level or duration of immunity following natural clearance of chlamydia has also been

90 identified as an important factor influencing projections of the effects of interventions (Geisler 91

et al., 2013; Omori et al., 2018; Smid et al., 2019). 92

We take an innovative approach that addresses these earlier limitations in order to adequately 93 quantify the expected effects of different PN strategies on chlamydia transmission. To this end, 94 we developed a novel deterministic, population-based chlamydia transmission model that can be 95 calibrated to multiple data sources within a Bayesian framework. The model includes a dedicated 96 PN module that tracks the most recent partners of index cases and can identify the index-partner 97 combinations that result in the largest effect of PN on reducing chlamydia prevalence. The 98 objectives of this study were to estimate the expected proportions of chlamydia positivity in 99 partners of people with diagnosed chlamydia (index cases) and to quantify the effects of APT on 100

chlamydia prevalence compared with standard PN in Britain. 101

#### METHODS 102

#### Chlamydia transmission model 103

We developed a deterministic, population-based model of chlamydia transmission between people of the opposite-sex (Fig 1). The model can be described by the following set of ordinary differential equations (ODEs):

$$\frac{dS_{ij}}{dt} = \mu N_{ij} - \lambda_{ij} S_{ij} + \sigma_i (I_{S,ij} + P_{S,ij}) + \tau_i (I_{S,ij} + I_{A,ij} + P_{S,ij} + P_{A,ij}) + \nu_i (P_{S,ij} + P_{A,ij}) + \omega_i R_{ij} - \mu S_{ij},$$
(1)

$$\frac{\mathrm{d}I_{S,ij}}{\mathrm{d}t} = f_i \lambda_{ij} S_{ij} - \kappa_{S,ij} - (\sigma_i + \tau_i + \mu) I_{S,ij},\tag{2}$$

$$\frac{\mathrm{d}I_{A,ij}}{\mathrm{d}t} = (1 - f_i)\lambda_{ij}S_{ij} - \kappa_{A,ij} - (\gamma_i + \tau_i + \mu)I_{A,ij},\tag{3}$$

$$\frac{\mathrm{d}P_{S,ij}}{\mathrm{d}t} = \kappa_{S,ij} - (\nu_i + \sigma_i + \tau_i + \mu)P_{S,ij},\tag{4}$$

$$\frac{\mathrm{d}P_{A,ij}}{\mathrm{d}t} = \kappa_{A,ij} - (\nu_i + \gamma_i + \tau_i + \mu)P_{A,ij},\tag{5}$$

$$\frac{\mathrm{d}R_{ij}}{\mathrm{d}t} = \gamma_i (I_{A,ij} + P_{A,ij}) - (\omega_i + \mu)R_{ij},\tag{6}$$

where  $S_{ij}$  are susceptible individuals of sex *i* and sexual activity group *j*, and  $N_{ij}$  denotes the respective population size. A fraction  $f_i$  of newly infected individuals is symptomatic  $(I_{S,ii})$ and seeks treatment at rate  $\sigma_i$  or gets tested and treated at rate  $\tau_i$ . Asymptomatically infected individuals  $(I_{A,ij})$  are tested and treated at  $\tau_i$  or clear the infection spontaneously at rate  $\gamma_i$ . Symptomatically and asymptomatically infected individuals can be notified by by chlamydiapositive index cases at rates  $\kappa_{S,ij}$  and  $\kappa_{A,ij}$  (see Section Partner notification). Notified individuals  $P_{S,ij}$  and  $P_{A,ij}$  are treated at rate  $v_i$ . Spontaneous clearance of asymptomatic infection results in the development of immunity  $(R_{ij})$ , which is lost at rate  $\omega_i$ . All individuals enter and leave the population at rate  $\mu$ . The force of infection is given by


$$\lambda_{ij} = c_{ij} \sum_{j'=1}^{n} \beta_{i'j'j} \rho_{ii'jj'} \frac{I_{S,i'j'} + I_{A,i'j'} + P_{S,i'j'} + P_{A,i'j'}}{N_{i'j'}}.$$
(7)

Here,  $\beta_{i'j'j}$  represents the per partnership transmission probability from sex i' to i and between sexual activity group j' and j, and  $c_{ij}$  is the sexual partner change rate for individuals of sex i medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

and sexual activity group *j*.  $\rho_{ii'jj'}$  represents the elements of the sexual mixing matrix (Garnett et al., 1999)

$$\rho_{ii'jj'} = \varepsilon \delta_{jj'} + (1-\varepsilon) \frac{c_{i'j'} N_{i'j'}}{\sum_{k=1}^{n} c_{i'k} N_{i'k}},\tag{8}$$

where  $\delta_{jj'}$  denotes the Kronecker delta (it is equal to 1 if j = j' and to 0 otherwise). Sexual mixing between activity groups can vary from proportionate ( $\varepsilon = 0$ ) to fully assortative ( $\varepsilon = 1$ ).



**Figure 1.** Schematic illustration of chlamydia transmission model. Susceptible individuals  $S_{ij}$  can become symptomatically and asymptomatically infected ( $I_{S,ij}$  and  $I_{A,ij}$ ). Infected individuals can then become notified ( $P_{S,ij}$  and  $P_{A,ij}$ ) by their partners. All infected individuals can receive treatment to become susceptible again, or acquire temporal immunity ( $R_{ij}$ ) through spontaneous clearance of the infection. Movement of individuals into and out of the population is omitted in the scheme. Subscripts *i* and *j* denote sex and sexual activity group, respectively.

### Partner notification (PN) module and Who-Notifies-Whom (WNW) matrix

Symptomatically and asymptomatically infected individuals  $(I_{S,ij} \text{ and } I_{A,ij})$  can be notified by 107 chlamydia-positive index cases. These index cases who are treated because of symptoms ( $\sigma$ ) 108 or asymptomatic testing ( $\tau$ ) initiate PN of their most recent sexual partner (Fig 2). To describe 109 this process in the transmission model, we constructed a Who-Notifies-Whom (WNM) matrix 110 in PN module. For simplicity, we assumed that PN is offered to index cases only, and not to 111 their notified partners. We further assumed that sexual partners of index cases have not left the 112 population since their last sexual contact. The entries of the WNW matrix can be computed 113 using the following algorithm: 114

115 1. Consider index cases 
$$(I_{S,i'j'}, I_{A,i'j'})$$
 who can notify their most recent sexual partners that  
116 are infected  $(I_{S,ij}, I_{A,ij}, I_{S,n,ij})$ .


117 2. Compute the average duration from infection of an index case until diagnosis:  $D_{S,i'} = \frac{1}{\sigma_{i'} + \tau_{i'}}$ 118 and  $D_{A,i'} = \frac{1}{\gamma_{i'} + \tau_{i'}}$ .

3. Compute the probability that an index case's most recent sexual contact was with their infector:  $p_X = e^{-c_{i'j'}D_{X,i'}}$ , with  $X = \{S, A\}$ .

21	(a) Determine the type of infector based on the index case's force of infection.
----	--

- (b) Compute the probability that the infection has not yet been cleared in the infector.
- 4. With probability  $1 p_X$ , the index case's most recent sexual contact was with an infectee or a other individual.
- (a) Determine the type of infectee and other individual based on the index case's force
   of infection.
- (b) Compute the probability that the infection has not yet been cleared in the infectee or
   the other individual.

Finally, we multiplied the WNW matrix with the numbers for each index case, the index cases' rate of diagnoses as defined by  $\sigma_{i'}$  and  $\tau_{i'}$ , and the index cases' proportion of treated partners  $f_{P,i'}$ . Summing over all sexual partners of index cases, we obtained the rates  $\kappa_{S,ij}$  and  $\kappa_{A,ij}$  at which symptomatically and asymptomatically infected partners of index cases are notified, respectively.



**Figure 2.** Schematic illustration of partner notification. An index case can either notify their infector (from whom they got infected), an infectee (who got infected by the index case), or another individual (who can either be infected or not). Infector, infectee and other infected individuals can clear the infection before they are notified.

# 133 Data and parameter priors

12

We estimated sexual behaviour parameters and chlamydia prevalence from Natsal-3, a population-134 based probability sample survey of sexual attitudes and lifestyles conducted among the resident 135 population in Great Britain from 2010 to 2012 (Erens et al., 2013; Mercer et al., 2013). The 136 full sample consists of 15,162 women and men aged 16-74 years. A subsample of participants 137 aged 16-44 years who reported at least one sexual partner over their lifetime were asked to 138 provide urine samples, resulting in laboratory confirmed chlamydia test results from 2,665 139 women and 1,885 men (Sonnenberg et al., 2013). We restricted our analysis to 16-34 years old 140 women (n = 2,138) and men (n = 1,533), which corresponds to the considered age range in the 141 transmission model. We used individual weights to adjust for unequal selection probabilities 142 and to correct for the age, gender and regional profiles in the survey sample. The full datasets of 143 both surveys are available from the UK Data Service Archive at the University of Essex (http: 144 //ukdataservice.ac.uk, study number SN7799). The sexual behaviour parameters 145  $(p \text{ and } c_{ii})$  were estimated from Natsal-3 using a maximum likelihood method as described 146 previously (Althaus et al., 2012a). For the other model parameters, we either used appropriate 147 prior distributions based on literature values or uninformed priors (Table 1). 148

Parameter	Description	Sex	Reference	Prior distribution	Prior (mean, IQR)	Posterior (mean, IQR)
$1/\mu$	Age range of population (16–34 year olds)	-	_	-	19 y	-
p	Proportion high sexual activity group	-	Estimated from Natsal-3	Multivariate normal	6.7% (5.5%-8.2%)	6.7% (6.5%-7.4%)
ε	Sexual mixing coefficient	-	_	$\mathscr{U}(0,1)$	0.5 (0.25-0.75)	0.43 (0.28-0.55)
$c_{11}$	Opposite-sex partner change rate (low)	Female	Estimated from Natsal-3	Multivariate normal	$0.41 (0.38-0.44) y^{-1}$	0.41 (0.40–0.42) y <sup>-1</sup>
$c_{21}$	Opposite-sex partner partner change rate (low)	Male	Estimated from Natsal-3	Multivariate normal	$0.41 (0.38-0.44) y^{-1}$	0.41 (0.40–0.42) y <sup>-1</sup>
$c_{12}$	Opposite-sex partner partner change rate (high)	Female	Estimated from Natsal-3	Multivariate normal	5.09 (4.60–5.63) $y^{-1}$	5.1 (4.9–5.2) y <sup>-1</sup>
c <sub>22</sub>	Opposite-sex partner partner change rate (high)	Male	Estimated from Natsal-3	Multivariate normal	5.09 (4.60–5.63) $y^{-1}$	5.1 (4.9–5.2) $y^{-1}$
$\beta_{111}$	Per partnership transmission probability (low)	Female	_	$\mathscr{U}(\boldsymbol{\beta}_{122},1)$	75% (62%–93%)	80% (62%-93%)
$\beta_{211}$	Per partnership transmission probability (low)	Male	_	$\mathscr{U}(\boldsymbol{\beta}_{122},1)$	75% (62%–93%)	94% (87%-97%)
$\beta_{112}$	Per partnership transmission probability (low-high)	Female	_	$\sqrt{eta_{111}eta_{122}}$	59% (39%-81%)	65% (48%-81%)
$\beta_{212}$	Per partnership transmission probability (low-high)	Male	_	$\sqrt{\beta_{211}\beta_{222}}$	59% (39%-81%)	86% (77%-94%)
$\beta_{122}$	Per partnership transmission probability (high)	Female	_	$\mathscr{U}(0,1)$	50% (25%-75%)	55% (36%-75%)
$\beta_{222}$	Per partnership transmission probability (high)	Male	-	$\mathscr{U}(0,1)$	50% (25%-75%)	81% (68%-91%)
$f_1$	Frequency of symptomatic infection	Female	_	$\mathscr{U}(0,1)$	50% (25%-75%)	10% (4%-18%)
$f_2$	Frequency of symptomatic infection	Male	_	$\mathscr{U}(0,1)$	50% (25%-75%)	28% (13%-44%)
$1/\sigma_1$	Average duration of symptomatic infection	Female	Davies et al. (2014)	𝔐(14,42) d	28 (21–35) d	28 (21–35) d
$1/\sigma_2$	Average duration of symptomatic infection	Male	Davies et al. (2014)	$\mathscr{U}(14, 42) d$	28 (21–35) d	28 (21–35) d
$1/\gamma_1$	Average duration of asymptomatic infection	Female	Price et al. (2013)	$1/\Gamma(100, 135.1)$ y	1.36 (1.27–1.45) y	1.37 (1.29–1.48) y
$1/\gamma_2$	Average duration of asymptomatic infection	Male	Lewis et al. (2017)	$1/\Gamma(2,4.8)$ y	4.78 (1.78–5.00) y	1.59 (1.23–2.11) y
$1/\omega_1$	Average duration of immunity	Female	Omori et al. (2018); Smid et al. (2019)	$\Gamma(2,0.4)$ y	5.0 (2.41–6.74) y	5.1 (3.4–7.3) y
$1/\omega_2$	Average duration of immunity	Male	Omori et al. (2018); Smid et al. (2019)	$\Gamma(2,0.4)$ y	5.0 (2.41–6.74) y	5.0 (3.1–7.8) y
$ au_1$	Treatment rate	Female	Chandra et al. (2017)	$\Gamma(1, 3.3) \text{ y}^{-1}$	$0.3 (0.09-0.42) y^{-1}$	$0.08 (0.03-0.15) y^{-1}$
$ au_2$	Treatment rate	Male	Chandra et al. (2017)	$\Gamma(1, 10) \text{ y}^{-1}$	$0.1 (0.03-0.14) y^{-1}$	$0.05 (0.02 - 0.10) \text{ y}^{-1}$
$f_{P,1}$	Number of treated partners	Female	Public Health England (2016)	Beta(5,4.4)	0.53 (0.42-0.64)	0.52 (0.40-0.62)
$f_{P,2}$	Number of treated partners	Male	Public Health England (2016)	Beta(5,4.4)	0.53 (0.42-0.64)	0.49 (0.38-0.61)
$1/v_1$	Time to partner treatment	Female	Public Health England (2016)	-	3.2 d	-
$1/v_2$	Time to partner treatment	Male	Public Health England (2016)	-	3.2 d	-

The first subscript *i* refers to sex (1: female; 2: male) and the second subscript *j* refers to the sexual activity group (1: low; 2: high).

# perpetuity. It is made available under a CC-BY 4.0 International license

#### Model calibration, scenarios and APT 149

We calibrated the model to chlamydia prevalence using Approximate Bayesian Computation 150 (ABC) (Beaumont, 2010). We sampled 10<sup>6</sup> parameter sets from the prior distributions (Table 151 1), and used a basic rejection algorithm to select the parameter sets that result in chlamydia 152 prevalences within a specified range (Fingerhuth et al., 2016). We considered the following 153 calibration scenarios: 154

- 1. Baseline scenario: Calibration to sex- and activity group-specific prevalence in the presence 155 (current situation) and absence of control interventions. 156
- 2. Calibration to sex-specific prevalence in the presence (current situation) and absence of 157 control interventions. 158
- 3. Calibration to sex-specific prevalence in the presence of control interventions (current 159 situation). 160

The estimated chlamydia prevalence from Natsal-3 was 2.2% (95% CI: 1.6%-2.8%) in women 161 and 1.5% (95% CI: 1.0%–2.2%) in men. For the calibration to sex-specific prevalence in presence 162 of control interventions, we accepted those parameter sets where the modelled prevalence was 163 within the 95% CI of these estimates. For the calibration to activity group-specific prevalence in 164 present of control interventions, we assumed that the prevalence in the high activity group cannot 165 exceed 15% in both women and men. Finally, for the calibration to sex-specific prevalence 166 in absence of control interventions, we assumed that the prevalence cannot exceed the point 167 estimate from Natsal-3 by more than twofold (Rönn et al., 2019). 168

We simulated the effects of APT on chlamydia transmission by 1) increasing the number of 169 treated partners by 5%, 10%, 15%, 20% and 25%, and 2) reducing the time to partner treatment 170 by 1, 2 and 3 days compared to standard PN. We then calculated the relative reduction in 171 prevalence 5 years after the implementation of APT. 172

We considered scenario 1 as our baseline scenario in the main text and provide all results 173 for scenario 2 and 3 in Supporting Information. Model simulations were performed in the R 174 software environment for statistical computing (R Core Team, 2016) using the function ode 175 from the package deSolve (Soetaert et al., 2010). Simulations were run on UBELIX (http:// 176 www.id.unibe.ch/hpc), the high-performance computing cluster at the University of Bern. 177 All data and R code files are available on GitHub: https://github.com/calthaus/ 178 chlamvdia-pn. 179


### RESULTS 180

#### Model calibration 181

Calibrating the transmission model to the three scenarios resulted in different posterior distribu-182 tions of chlamydia prevalence (Figs 3, S1 and S2) and model parameters (Table 1, Figs 4, S3 and 183 S4). In our baseline scenario (scenario 1), the median prevalence of chlamydia in presence of 184 control interventions was 1.84% (95% credible interval, CrI: 1.60%–2.62%) in women and 1.78% 185 (95% CrI: 1.13%–2.14%) in men. The per partnership transmission probabilities were higher 186 for women (male-female transmission) than men (female-male transmission). Sexual mixing 187 between sexual activity groups was weakly assortative (median: 0.43, interguartile range (IOR): 188 0.28–0.55). 10% (IQR: 4%–18%) of infections were symptomatic in women, compared to 28% 189 (IQR: 13%-44%) in men. The average duration of asymptomatic infection was slightly longer 190 in men (580 d, IQR: 450-470 days) than women (500 d, IQR: 470-540 days). Treatment rates 191 were 0.08  $y^{-1}$  (IQR: 0.03–0.15  $y^{-1}$ ) and 0.05  $y^{-1}$  (IQR: 0.02–0.10  $y^{-1}$ ) for women and men, 192

perpetuity. It is made available under a CC-BY 4.0 International license .

respectively. For all other parameters, the posterior distributions did not differ substantially from the prior distribution. The alternative calibration scenarios (scenario 2 and 3) where characterised by more assortative mixing, longer durations of asymptomatic infection, and shorter durations of immunity (Figs S3 and S4). Together, this resulted in a somewhat unrealistically high and low chlamydia prevalence in the high and low sexual activity group, respectively (Figs S1 and S2). Hence, we concluded that the baseline scenario (scenario 1) seems most adequate to describe chlamydia transmission between people of the opposite-sex and to quantify the effects of PN.




**Figure 3.** Posterior distributions of chlamydia prevalence (baseline scenario 1). Modelled prevalence in the presence and absence of interventions (asymptomatic treatment and partner notification) is shown as dark and light shaded areas. The black dot represents the prevalence for 16–34 year olds as estimated from Natsal-3 (together with 95% confidence intervals).

### 200 Who-Notifies-Whom (WNW) matrix

The PN module allowed us to construct the WNM matrix for female and male index cases (Tables 201 2 and 3). This matrix provides the chlamydia positivity in partners of index cases, stratified by 202 the sexual activity group and the infection status of both index case and partner. Furthermore, 203 we calculated the proportion of PNs that were initiated and the proportion of positive partners 204 that were notified by each index case. For example, the overall chlamydia positivity in a male 205 sexual partner of a female symptomatic index case of the low sexual activity group is 90% 206 (IQR: 88%–93%) (most left column in Table 2). Most sexual partners of these index cases are 207 asymptomatic men of the high sexual activity group (71%, IQR: 68%–74%). Symptomatically 208 infected women of the low sexual activity group notify 28% (IQR: 16%–40%) of all male sexual 209 partners. Due to the high chlamydia positivity in these partners, this index-partner combination 210 contributes to 42% (IQR: 29%–51%) of all PNs that identify a chlamydia-positive partner. In 211 summary, we can show that chlamydia positivity is highest in sexual partners of symptomatic 212

medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



**Figure 4.** Prior and posterior distributions of model parameters (baseline scenario 1). Prior (green) and posterior distributions for females (red) and males (blue). The sexual mixing coefficient is the same for both sexes. Numbers below the horizontal axes represent the median and interquartile range.

<sup>213</sup> index cases that belong to the low sexual activity group. The notified partners are typically

- <sup>214</sup> asymptomatic and belong to the high sexual activity group, i.e., are those infected individuals
- that will contribute most to onward transmission. This general pattern is even more accentuated

<sup>216</sup> if index cases are men (3).

		Index (female)			
		Symptomatic		Asymptomatic	
Partner (male)		Low	High	Low	High
Overall chlamydia positivity in partner		90% (88%-93%)	73% (68%-79%)	29% (21%-36%)	31% (26%-37%)
Proportion symptomatic partners	Low	0% (0%–0%)	0% (0%-0%)	0% (0%–0%)	0% (0%-1%)
	High	1% (0%-1%)	1% (0%-2%)	0% (0%–0%)	0% (0%-1%)
Proportion asymptomatic partners	Low	17% (15%-21%)	6% (4%-9%)	7% (5%-10%)	10% (7%-15%)
	High	71% (68%–74%)	65% (60%-71%)	21% (16%-26%)	19% (15%-23%)
Proportion of all notified partners		28% (16%-40%)	28% (16%-40%)	22% (10%-36%)	18% (8%-29%)
Proportion of all notified and positive partners		42% (29%-51%)	33% (24%-42%)	10% (4%-23%)	9% (4%-18%)

**Table 2.** Who-Notifies-Whom (WNW) matrix for female index cases (scenario 1). Example: The overall chlamydia positivity in a male sexual partner of a female symptomatic index case of the low sexual activity group is 90%. The same index cases notify 28% of all male sexual partners, contributing to 42% of all notified and positive partners. Numbers are given as median and interquartile range.

## **APT intervention**

Simulating the effects of APT on chlamydia transmission illustrates that it can be an effective method to reduce prevalence at the population-level (Fig 5). Increasing the numbers of treated partners from current levels in Britain (0.51, 95% CrI: 0.21–0.80, see Table 1) can result in

<sup>221</sup> a considerable reduction in prevalence after 5 years. For example, an increase of 25% would

reduce chlamydia prevalence by 18% (95% CrI: 5%-44%) in both women and men. The relative

reduction is slightly higher in women than men, and in high sexual activity individuals compared

perpetuity. It is made available under a CC-BY 4.0 International license

		Index (male)			
		Symptomatic		Asymptomatic	
Partner (female)		Low	High	Low	High
Overall chlamydia positivity in partner		91% (88%-93%)	79% (75%-83%)	20% (14%-29%)	47% (41%-53%)
Proportion symptomatic partners	Low	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)
	High	0% (0%-1%)	0% (0%-1%)	0% (0%-0%)	0% (0%-0%)
Proportion asymptomatic partners	Low	20% (17%-24%)	9% (6%-12%)	7% (6%–9%)	18% (14%-23%)
	High	70% (66%-73%)	69% (63%-74%)	13% (8%-21%)	28% (24%-32%)
Proportion of all notified partners		40% (31%-48%)	41% (30%-49%)	7% (2%-18%)	6% (2%-15%)
Proportion of all notified and positive partners		48% (40%-54%)	42% (34%-49%)	2% (0%-6%)	4% (1%-10%)

**Table 3.** Who-Notifies-Whom (WNW) matrix for male index cases (scenario 1). Example: The overall chlamydia positivity in a female sexual partner of a male symptomatic index case of the low sexual activity group is 91%. The same index cases notify 40% of all female sexual partners, contributing to 48% of all notified and positive partners. Numbers are given as median and interquartile range.

224 to low sexual activity individuals. The results show that the effects of APT on chlamydia

transmission mainly stem from increasing the numbers of treated partners, as reducing the time

to partner treatment from current levels (3.2 d, see Table 1) had only minor effects on chlamydia

prevalence. Compared to the baseline scenario (scenario 1), the effects of APT were somewhat

lower in scenario 2 (Fig S6) but higher in scenario 3 (Fig S5).

# 229 DISCUSSION

Using a novel chlamydia transmission model, we explored the expected effects of APT on 230 chlamydia prevalence compared to standard PN in Britain. We found that chlamydia positivity is 231 highest in partners of symptomatic index cases with low sexual activity, whereas the infected 232 partners are typically asymptomatic and highly sexually active. Conducting PN for this particu-233 lar index-partner combination will thus be most effective for preventing further transmission. 234 Increasing the number of treated partners from current levels by 25% would reduce chlamydia 235 prevalence by 18% (95% CrI: 5%-44%) in both women and men within 5 years. In contrast, 236 reducing the time to partner treatment alone had a minor effect on reducing prevalence. Together, 237 these results suggest that PN typically identifies sexual partners that are likely to further transmit 238 chlamydia, and that APT in particular has the potential to further reduce prevalence through an 239 increase in PN uptake. 240

The main strength of our model is the PN module, which allowed us to construct a WNW 241 matrix and look into the process of PN for chlamydia in great detail. In contrast to other 242 modelling studies, we used the PN module to identify the index-partner combinations that result 243 in the highest chlamydia positivity in partners and yield the greatest impact on reducing further 244 transmission. Compared to other deterministic, population-based modelling approaches that 245 limit PN to current sexual partners (Heijne et al., 2011; Rönn et al., 2019), our model allowed us 246 to track the most recent partner for all index cases. Using a Bayesian modelling framework, we 247 were also able to account for the considerable uncertainty in model parameters. Consideration of 248 the specific distribution of chlamydia infections according to an individual's sexual activity, has 249 been suggested as an important aspect of STI transmission models (Althaus et al., 2012b). We 250 therefore calibrated the model, not only to the current chlamydia prevalence in women and men, 251 but also to chlamydia prevalence in different sexual activity groups and the expected chlamydia 252 prevalence in the absence of asymptomatic testing and PN. The modelling framework can be 253 further adapted for calibration to additional epidemiological data, such as chlamydia positivity 254 in partners of index cases, and can therefore be tailored to the results of randomised controlled 255 trials. 256

medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license




Figure 5. Projected effect of accelerated partner therapy (APT) on chlamydia prevalence after 5 years (baseline scenario 1). APT is modelled as an increase in the number of treated partners (left panels) or a reduction in the time to partner treatment (right panels). Changes in prevalence are given for females (red) and males (blue). Note the difference in scales of the axes between the left and right panels.

Our study has some limitations. First, we considered notification of the index case's most 257 recent partner only. This was a necessary simplification of our modelling framework. As the 258 average number of notified partners is typically below one, we expect that including notification 259 of additional partners in our model would not substantially affect our results. Second, we 260 did not consider reinfection of index case cases by untreated partners. The modelled effects 261 of APT on reducing chlamydia prevalence could thus be considered as best-case scenarios. 262 Third, we did not consider different age groups and age-specific sexual mixing patterns (Smid 263 et al., 2018), men having sex with men (MSM) or different ethnic groups in our model. As 264 most chlamydia infections are found in the population of young opposite-sex partners, and 265 because sexual mixing is arguably the most critical aspect for PN, we do not think that ignoring 266

perpetuity. It is made available under a CC-BY 4.0 International license .

these additional complexities would substantially impact our results. Finally, there remains considerable uncertainty with respect to test uptake, chlamydia diagnoses (Chandra et al., 2017) and their impact on chlamydia prevalence (Lewis and White, 2018; Smid et al., 2019). We addressed this problem by choosing broad prior distributions for the treatment rate in our model.

The modelled chlamydia positivity in partners of index cases, which is typically not reported 271 for modelling studies, is in good agreement with empirical data from Britain that show an overall 272 positivity of 62% (Public Health England, 2016) and 69% (Public Health England, 2018). While 273 these values correspond to the overall positivity, the WNW matrix highlights that chlamydia 274 positivity is expected to be higher in partners of symptomatic index cases, but lower in partners 275 of asymptomatic index cases. The precise contribution of PN on limiting the spread of chlamydia 276 remains a matter of debate (Althaus et al., 2014; Rönn et al., 2017). In this study, and similar to 277 the results from Rönn et al. (2019), we found that PN in general can play an important role in 278 reducing the burden of chlamydia. 279

We showed that APT could effectively reduce ongoing chlamydia transmission in Britan 280 through an increase in the numbers of partners treated. Current levels of PN uptake (the number 281 of contacts per index case who were reported as having attended a sexual health service within 282 four working weeks of the date of the PN consultation) are below the standard of 0.6 (Public 283 Health England, 2018) which suggests that methods that aim to increase uptake to this level and 284 beyond should be considered for PN. Furthermore, it will be important to continue monitoring 285 the levels of PN uptake over time. In contrast to increasing PN uptake, reducing the time to 286 partner treatment appears to be less critical for increasing the effectiveness of PN. Average times 287 for attending health services are already quite short (3.2 days, (Public Health England, 2016)), 288 but APT might still offer substantial benefits in situations where there are longer delay periods. 289 Our study highlights that PN for chlamydia is a highly effective intervention due to its targeted 290 approach. With the WNW matrix, we can show that PN naturally identifies the most important 291 partners of index cases: asymptomatically infected individuals from the high sexual activity 292 group who thus remain infected for a long time period and have a high sexual partner change 293 rate. 294

A detailed understanding of the effects of PN on chlamydia transmission is critical for implementing optimal control strategies. The presented modelling framework can be used to study the population-level effects of different PN interventions, such as APT, in considerable detail, and is flexible enough to be readily adapted to different populations and intervention scenarios. Our results suggest that APT, through an increase in the number of partners treated, would be an effective method to reduce ongoing chlamydia transmission in Britain.

## **301** Acknowledgments

Calculations were performed on UBELIX (http://www.id.unibe.ch/hpc), the HPC cluster at the University of Bern. Natsal-3 is a collaboration between University College London, London School of Hygiene and Tropical Medicine, National Centre for Social Research, Public Health England, and the University of Manchester. We thank the study participants, the team of interviewers from NatCen Social Research, and operations and computing staff from NatCen Social Research. The Natsal-3 study was approved by the Oxfordshire Research Ethics Committee A (Ref: 10/H0604/27).

# 309 Funding

This study was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research (Grant Reference Number RP-PG-0614-20009). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license

#### Competing interests 314

None. 315

#### Author contributions 316

All authors conceived and designed the study. CLA developed the mathematical model, per-317

formed model simulations, and wrote the manuscript. All authors contributed to the interpretation 318

of the results, commented on the manuscript, and approved the final version of the manuscript. 319

### REFERENCES 320

Althaus, C., Turner, K., Mercer, C., Auguste, P., Roberts, T., Bell, G., Herzog, S., Cassell, J., 321 Edmunds, J., White, P., Ward, H., and Low, N. (2014). Effectiveness and cost-effectiveness of 322 traditional and new partner notification technologies for curable sexually transmitted infections: 323 observational study, systematic reviews and mathematical modelling. Health Technol Assess, 324 18(2). 325

- Althaus, C. L., Heijne, J. C., Herzog, S. A., Roellin, A., and Low, N. (2012a). Individual 326
- and population level effects of partner notification for Chlamydia trachomatis. PLoS One, 327 7(12):e51438. 328
- Althaus, C. L., Turner, K. M. E., Schmid, B. V., Heijne, J. C. M., Kretzschmar, M., and Low, N. 329 (2012b). Transmission of Chlamydia trachomatis through sexual partnerships: a comparison 330

between three individual-based models and empirical data. J R Soc Interface, 9(66):136-146. 331

- Beaumont, M. A. (2010). Approximate Bayesian Computation in Evolution and Ecology. Annual 332 Review of Ecology, Evolution, and Systematics, 41(1):379–406. 333
- Cates, W. J. and Wasserheit, J. N. (1991). Genital chlamydial infections: epidemiology and 334 reproductive sequelae. Am J Obstet Gynecol, 164(6 Pt 2):1771-1781. 335

Chandra, N. L., Soldan, K., Dangerfield, C., Sile, B., Duffell, S., Talebi, A., Choi, Y. H., Hughes, 336 G., and Woodhall, S. C. (2017). Filling in the gaps: estimating numbers of chlamydia tests and 337 diagnoses by age group and sex before and during the implementation of the English National 338

- Screening Programme, 2000 to 2012. Euro Surveill, 22(5). 339
- Davies, B., Anderson, S.-J., Turner, K. M. E., and Ward, H. (2014). How robust are the natural 340 history parameters used in chlamydia transmission dynamic models? A systematic review. 341 Theor Biol Med Model, 11:8. 342
- Erens, B., Phelps, A., Clifton, S., Mercer, C. H., Tanton, C., Hussey, D., Sonnenberg, P., 343 Macdowall, W., Field, N., Datta, J., Mitchell, K., Copas, A. J., Wellings, K., and Johnson, 344
- A. M. (2013). Methodology of the third British National Survey of Sexual Attitudes and 345
- Lifestyles (Natsal-3). Sexually Transmitted Infections, pages sextrans-2013-051359. 346
- Estcourt, C., Sutcliffe, L., Cassell, J., Mercer, C. H., Copas, A., James, L., Low, N., Horner, P., 347

Clarke, M., Symonds, M., Roberts, T., Tsourapas, A., and Johnson, A. M. (2012). Can we 348 improve partner notification rates through expedited partner therapy in the UK? Findings from 349

- an exploratory trial of Accelerated Partner Therapy (APT). Sex Transm Infect, 88(1):21-6. 350
- Estcourt, C. S., Howarth, A. R., Copas, A., Low, N., Mapp, F., Woode Owusu, M., Flowers, P., 351 Roberts, T., Mercer, C. H., Wayal, S., Symonds, M., Nandwani, R., Saunders, J., Johnson,
- 352 A. M., Pothoulaki, M., Althaus, C., Pickering, K., McKinnon, T., Brice, S., Comer, A., 353
- Tostevin, A., Ogwulu, C. D., Vojt, G., and Cassell, J. A. (2020). Accelerated partner therapy
- 354
- (apt) partner notification for people with chlamydia trachomatis: protocol for the limiting 355 undetected sexually transmitted infections to reduce morbidity (lustrum) apt cross-over cluster 356
- randomised controlled trial. BMJ Open, 10(3):e034806. 357
- Estcourt, C. S., Sutcliffe, L. J., Copas, A., Mercer, C. H., Roberts, T. E., Jackson, L. J., Symonds, 358
- M., Tickle, L., Muniina, P., Rait, G., Johnson, A. M., Aderogba, K., Creighton, S., and Cassell, 359

perpetuity. It is made available under a CC-BY 4.0 International license

- J. A. (2015). Developing and testing accelerated partner therapy for partner notification for 360
- people with genital chlamydia trachomatis diagnosed in primary care: a pilot randomised 361
- controlled trial. Sex Transm Infect, 91(8):548-54. 362
- Ferreira, A., Young, T., Mathews, C., Zunza, M., and Low, N. (2013). Strategies for partner 363 notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev, 364 (10):CD002843. 365
- Fingerhuth, S. M., Bonhoeffer, S., Low, N., and Althaus, C. L. (2016). Antibiotic-Resistant 366 Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners. PLoS 367 Pathog, 12(5):e1005611. 368
- Garnett, G. P., Mertz, K. J., Finelli, L., Levine, W. C., and St Louis, M. E. (1999). The 369 transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients 370 from Newark, New Jersey. Philos Trans R Soc Lond B Biol Sci, 354(1384):787-97. 371
- Geisler, W. M., Lensing, S. Y., Press, C. G., and Hook, E. W. (2013). Spontaneous resolution 372
- of genital Chlamydia trachomatis infection in women and protection from reinfection. The 373 Journal of Infectious Diseases, 207(12):1850–1856. 374
- Golden, M. R., Kerani, R. P., Stenger, M., Hughes, J. P., Aubin, M., Malinski, C., and Holmes, 375
- K. K. (2015). Uptake and population-level impact of expedited partner therapy (ept) on 376 chlamydia trachomatis and neisseria gonorrhoeae: the washington state community-level 377
- randomized trial of ept. PLoS Med, 12(1):e1001777. 378
- Golden, M. R., Whittington, W. L. H., Handsfield, H. H., Hughes, J. P., Stamm, W. E., Hogben, 379 M., Clark, A., Malinski, C., Helmers, J. R. L., Thomas, K. K., and Holmes, K. K. (2005). 380 Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial 381 infection. N Engl J Med, 352(7):676-85. 382
- Heijne, J. C. M., Althaus, C. L., Herzog, S. A., Kretzschmar, M., and Low, N. (2011). The role 383 of reinfection and partner notification in the efficacy of Chlamydia screening programs. J 384 Infect Dis, 203(3):372–7. 385
- Lewis, J., Price, M. J., Horner, P. J., and White, P. J. (2017). Genital chlamydia trachomatis 386 infections clear more slowly in men than women, but are less likely to become established. 387 The Journal of Infectious Diseases, 216(2):237-244. 388
- Lewis, J. and White, P. J. (2018). Changes in chlamydia prevalence and duration of infection es-389 timated from testing and diagnosis rates in england: a model-based analysis using surveillance 390 data, 2000-15. Lancet Public Health, 3(6):e271-e278. 391
- Low, N., Heijne, J. C. M., Herzog, S. A., and Althaus, C. L. (2014). Reinfection by untreated 392 partners of people treated for Chlamydia trachomatis and Neisseria gonorrhoeae: mathematical 393
- modelling study. Sex Transm Infect, 90(3):254-6. 394
- Mercer, C. H., Tanton, C., Prah, P., Erens, B., Sonnenberg, P., Clifton, S., Macdowall, W., 395 Lewis, R., Field, N., Datta, J., Copas, A. J., Phelps, A., Wellings, K., and Johnson, A. M. 396

(2013). Changes in sexual attitudes and lifestyles in Britain through the life course and over 397

- time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet, 398 382(9907):1781-94. 399
- Omori, R., Chemaitelly, H., Althaus, C. L., and Abu-Raddad, L. J. (2018). Does infection with 400
- chlamydia trachomatis induce long-lasting partial immunity? insights from mathematical 401 modelling. Sex Transm Infect. 402
- Organization, W. H. and on HIV/AIDS, J. U. N. P. (1999). Sexually transmitted diseases: policies 403 and principles for prevention and care. WHO/UNAIDS. 404
- Price, M. J., Ades, A. E., Angelis, D. D., Welton, N. J., Macleod, J., Soldan, K., Turner, K., 405
- Simms, I., and Horner, P. J. (2013). Mixture-of-exponentials models to explain heterogeneity 406
- in studies of the duration of Chlamydia trachomatis infection. Stat Med, 32(9):1547-60. 407

- perpetuity. It is made available under a CC-BY 4.0 International license
- Public Health England (2016). Partner notification in chlamydia screening National audit 408 report. 409
- Public Health England (2018). NCSP 2017 audit report Audit of standards: turnaround times, 410 partner notification and re-testing. 411
- R Core Team (2016). R: A Language and Environment for Statistical Computing. R Foundation 412 for Statistical Computing, Vienna, Austria. 413
- Roberts, T. E., Tsourapas, A., Sutcliffe, L., Cassell, J., and Estcourt, C. (2012). Is accelerated 414
- partner therapy (apt) a cost-effective alternative to routine patient referral partner notification 415
- in the uk? preliminary cost-consequence analysis of an exploratory trial. Sex Transm Infect, 416
- 88(1):16-20. 417
- Rönn, M. M., Tuite, A. R., Menzies, N. A., Wolf, E. E., Gift, T. L., Chesson, H. W., Torrone, 418
- E., Berruti, A., Mazzola, E., Galer, K., Hsu, K., and Salomon, J. A. (2019). The impact of 419 screening and partner notification on chlamydia in the united states, 2000-2015: Evaluation of 420
- epidemiologic trends using a pair-formation transmission model. Am J Epidemiol. 421
- Rönn, M. M., Wolf, E. E., Chesson, H., Menzies, N. A., Galer, K., Gorwitz, R., Gift, T., Hsu, K., 422 and Salomon, J. A. (2017). The use of mathematical models of chlamydia transmission to 423
- address public health policy questions. Sexually Transmitted Diseases, 44(5):278-283. 424
- Rowley, J., Vander Hoorn, S., Korenromp, E., Low, N., Unemo, M., Abu-Raddad, L. J., Chico, 425
- R. M., Smolak, A., Newman, L., Gottlieb, S., Thwin, S. S., Broutet, N., and Taylor, M. M. 426 (2019). Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence 427 estimates, 2016. Bull World Health Organ, 97(8):548-562P. 428
- Smid, J., Althaus, C. L., and Low, N. (2019). Discrepancies between observed data and predic-429
- tions from mathematical modelling of the impact of screening interventions on Chlamydia 430 trachomatis prevalence. Scientific Reports, 9(1):7547. 431
- Smid, J. H., Garcia, V., Low, N., Mercer, C. H., and Althaus, C. L. (2018). Age difference 432 between heterosexual partners in Britain: Implications for the spread of Chlamydia trachomatis. 433 Epidemics. 434
- Soetaert, K., Petzoldt, T., and Setzer, R. W. (2010). Solving differential equations in R: package 435 deSolve. Journal of Statistical Software, 33(9):1-25. 436
- Sonnenberg, P., Clifton, S., Beddows, S., Field, N., Soldan, K., Tanton, C., Mercer, C. H., 437
- da Silva, F. C., Alexander, S., Copas, A. J., Phelps, A., Erens, B., Prah, P., Macdowall, W., 438
- Wellings, K., Ison, C. A., and Johnson, A. M. (2013). Prevalence, risk factors, and uptake of 439
- interventions for sexually transmitted infections in Britain: findings from the National Surveys 440
- of Sexual Attitudes and Lifestyles (Natsal). Lancet, 382(9907):1795-806. 441

perpetuity. It is made available under a CC-BY 4.0 International license .

### **S1 SUPPORTING INFORMATION** 442

- S1.1 Model calibration 443
- S1.1.1 Chlamydia prevalence 444




Figure S1. Posterior distributions of chlamydia prevalence (baseline scenario 2). Modelled prevalence in the presence and absence of interventions (asymptomatic treatment and partner notification) is shown as dark and light shaded areas. The black dot represents the prevalence for 16-34 year olds as estimated from Natsal-3 (together with 95% confidence intervals).





Figure S2. Posterior distributions of chlamydia prevalence (baseline scenario 3). Modelled prevalence in the presence and absence of interventions (asymptomatic treatment and partner notification) is shown as dark and light shaded areas. The black dot represents the prevalence for 16-34 year olds as estimated from Natsal-3 (together with 95% confidence intervals).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .





**Figure S3.** Prior and posterior distributions of model parameters (baseline scenario 2). Prior (green) and posterior distributions for females (red) and males (blue). The sexual mixing coefficient is the same for both sexes. Numbers below the horizontal axes represent the median and interquartile range.




Figure S4. Prior and posterior distributions of model parameters (baseline scenario 3). Prior (green) and posterior distributions for females (red) and males (blue). The sexual mixing coefficient is the same for both sexes. Numbers below the horizontal axes represent the median and interquartile range.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

#### S1.1.3 Who-Notifies-Whom (WNW) matrix 446

Partner (male)		Index (female) Symptomatic Low	High	Asymptomatic Low	High
Uninfected		NA	NA	NA	NA
Symptomatic	Low	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)	0% (0%-1%)
	High	1% (0%-2%)	1% (0%-2%)	0% (0%-0%)	0% (0%-1%)
Asymptomatic	Low	20% (16%-25%)	3% (1%-6%)	10% (7%-14%)	6% (3%-10%)
	High	68% (64%-72%)	68% (62%-74%)	24% (18%-31%)	23% (18%-28%)
Chlamydia positivity in partner		91% (88%–93%)	74% (68%–79%)	35% (27%-45%)	31% (26%-36%)
Proportion of notified partners		18% (9%-31%)	37% (20%-52%)	13% (5%-27%)	21% (9%-36%)
Proportion positive among notified		29% (15%-43%)	42% (27%-56%)	7% (2%-20%)	11% (4%-22%)

Table S1. Who-Notifies-Whom (WNW) matrix for female index cases (scenario 3). Numbers are given as median and interquartile range.

Partner (female)		Index (male) Symptomatic Low	High	Asymptomatic Low	High
Uninfected		NA	NA	NA	NA
Symptomatic	Low	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)
	High	0% (0%-1%)	0% (0%-1%)	0% (0%-0%)	0% (0%-1%)
Asymptomatic	Low	21% (18%-25%)	4% (2%-9%)	6% (5%-8%)	11% (5%-18%)
	High	67% (63%-71%)	71% (65%–76%)	8% (3%-14%)	32% (26%-38%)
Chlamydia positivity in partner		90% (87%–92%)	78% (73%-82%)	15% (9%-22%)	45% (40%-53%)
Proportion of notified partners		27% (16%-39%)	48% (34%-63%)	6% (2%-16%)	8% (3%-20%)
Proportion positive among notified		35% (21%-47%)	50% (38%-64%)	1% (0%-4%)	5% (2%-14%)

Table S2. Who-Notifies-Whom (WNW) matrix for male index cases (scenario 3). Numbers are given as median and interquartile range.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Partner (male)		Index (female) Symptomatic Low	High	Asymptomatic Low	High
Uninfected		NA	NA	NA	NA
	T				
Symptomatic	Low	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)
	High	1% (0%-1%)	1% (0%-2%)	0% (0%-0%)	0% (0%-1%)
Asymptomatic	Low	22% (17%-27%)	2% (1%-4%)	10% (7%-14%)	5% (2%-9%)
	High	66% (62%-70%)	69% (63%-74%)	21% (16%-26%)	24% (19%–29%)
Chlamydia positivity in partner		91% (88%–93%)	73% (68%–79%)	32% (24%-40%)	31% (26%-35%)
Proportion of notified partners		14% (6%-27%)	38% (22%-56%)	11% (4%-23%)	24% (10%-40%)
Proportion positive among notified		24% (12%-38%)	45% (31%-62%)	6% (2%-14%)	13% (5%-26%)

Table S3. Who-Notifies-Whom (WNW) matrix for female index cases (scenario 2). Numbers are given as median and interquartile range.

Partner (female)		Index (male) Symptomatic Low	High	Asymptomatic Low	High
Uninfected		NA	NA	NA	NĂ
Symptomatic	Low	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)	0% (0%-0%)
• •	High	0% (0%-1%)	0% (0%-1%)	0% (0%-0%)	0% (0%-1%)
Asymptomatic	Low	22% (19%-27%)	3% (1%-6%)	7% (6%-9%)	8% (3%-14%)
	High	66% (62%-70%)	73% (68%–78%)	10% (5%-17%)	35% (28%-41%)
Chlamydia positivity in partner		90% (88%–92%)	78% (73%–82%)	18% (12%-25%)	45% (39%-51%)
Proportion of notified partners		24% (11%-36%)	53% (37%-68%)	4% (1%-11%)	9% (3%-21%)
Proportion positive among notified		31% (16%-43%)	54% (41%-70%)	1% (0%-3%)	5% (2%-14%)

Table S4. Who-Notifies-Whom (WNW) matrix for male index cases (scenario 2). Numbers are given as median and interquartile range.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .






Figure S5. Projected effect of accelerated partner therapy (APT) on chlamydia prevalence after 5 years (scenario 2). APT is modelled as an increase in the number of treated partners (left panels) or a reduction in the time to partner treatment (right panels). Changes in prevalence are given for females (red) and males (blue). Note the difference in scales of the axes between the left and right panels.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.07.20245142; this version posted December 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .




Figure S6. Projected effect of accelerated partner therapy (APT) on chlamydia prevalence after 5 years (scenario 3). APT is modelled as an increase in the number of treated partners (left panels) or a reduction in the time to partner treatment (right panels). Changes in prevalence are given for females (red) and males (blue). Note the difference in scales of the axes between the left and right panels.